Hoth Therapeutics (NASDAQ:HOTH) Issues Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) announced its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07, Zacks reports.

Hoth Therapeutics Price Performance

NASDAQ HOTH opened at $1.03 on Friday. The stock has a market capitalization of $7.11 million, a price-to-earnings ratio of -0.78 and a beta of 0.84. The business’s fifty day moving average is $1.13 and its 200-day moving average is $1.01. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80.

Analysts Set New Price Targets

HOTH has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a report on Thursday, January 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Monday, March 10th.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.